Pharmacy Times October 14, 2024
Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief

Key Takeaways

  • PBMs have shifted from administrative roles to profit-driven entities, focusing on in-house dispensing and rebate schemes.
  • The FTC has launched investigations into PBM practices, highlighting potential market misalignments and economic rents.
  • Transparency and value-based contracting are essential for PBMs to align with purchaser demands and ensure market functionality.
  • Community pharmacies face closures due to unfavorable PBM contracts, necessitating urgent industry changes to maintain access and sustainability.

PBMS ARE BUSINESSES, DESIGNED TO MAKE A RETURN ON EQUITY AND INVESTMENTS

Nearly every working or retired American owns a piece of a company with a pharmacy benefit manager (PBM). I frequently ask a room of pharmacy owners how many of them log into their brokerage or retirement accounts each...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
Medicare's $2K drug cap starts Jan. 1
CVS, Walgreens & Walmart's healthcare strategy faces headwinds: 10 notes from 2024
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Mark Cuban's 2025 plans

Share This Article